NCT02339779 (BREAST) is a NA clinical trial of autologous fat transfer in Breast Cancer, sponsored by Maastricht University Medical Center.

Who is sponsoring NCT02339779?

NCT02339779 is sponsored by Maastricht University Medical Center.

What drugs are being tested in NCT02339779?

Interventions in NCT02339779: autologous fat transfer, breast implant.

What condition does NCT02339779 study?

NCT02339779 studies Breast Cancer.

Is NCT02339779 still recruiting?

NCT02339779 is currently active, enrolled. Last updated 3 February 2022.

Last reviewed 2022-02-03 · How we verify

NCT02339779: BREAST

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

the Breast Reconstruction With External Pre-expansion and Autologous Fat Transfer Versus Standard Therapy Trial

Active, enrolled NA Last updated 3 February 2022

What this trial tests

NA trial testing autologous fat transfer in Breast Cancer in 196 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

1 October 2015

Primary endpoint
1 October 2026

1 October 2026

Quick facts

Lead sponsor	Maastricht University Medical Center
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	196
Start date	1 October 2015
Primary completion	1 October 2026
Estimated completion	1 October 2026
Sites	7 locations across Netherlands

Drugs / interventions tested

autologous fat transfer
breast implant

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

Maastricht University Medical Center

Who can join

18 and older, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Breast-related Quality of life (BREAST_Q)
Time frame: 1 year
Measured by the BREAST-Q questionnaire (quality of life subdivision) preoperatively and 1 year postoperatively

Sponsor's own description

This multicentre randomized controlled trial aims to evaluate a new breast reconstruction technique- autologous fat transfer (AFT). Female patients with breast cancer schedule to receive a mastectomy (or having undergone mastectomy in the past) will be randomized to undergo breast reconstruction with either AFT (intervention group) or reconstruction with implants (control group). AFT will be evaluated in terms of quality of life, aesthetic result, complications, oncological safety and cost-effectiveness.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Effect of Total Breast Reconstruction With Autologous Fat Transfer Using an Expansion Device vs Implants on Quality of Life Among Patients With Breast Cancer: A Randomized Clinical Trial.
Piatkowski AA, Wederfoort JLM, Hommes JE, Schop SSJ, et al · · 2023 · cited 24× · PMID 36857058 · DOI 10.1001/jamasurg.2022.7625
The Crosstalk Between Adipose-Derived Stem or Stromal Cells (ASC) and Cancer Cells and ASC-Mediated Effects on Cancer Formation and Progression-ASCs: Safety Hazard or Harmless Source of Tropism?
Guillaume VGJ, Ruhl T, Boos AM, Beier JP. · · 2022 · cited 23× · PMID 35274703 · DOI 10.1093/stcltm/szac002
BREAST trial study protocol: evaluation of a non-invasive technique for breast reconstruction in a multicentre, randomised controlled trial.
Schop SSJ, Hommes JE, Krastev TK, Derks D, et al · · 2021 · cited 14× · PMID 34531218 · DOI 10.1136/bmjopen-2021-051413
Aesthetic Evaluation of Breast Reconstruction with Autologous Fat Transfer vs. Implants.
Wederfoort JLM, Kleeven A, Hommes JE, Van Kuijk SMJ, et al · · 2023 · cited 6× · PMID 36100783 · DOI 10.1007/s00266-022-03076-2
Superior Sensibility after Full Breast Reconstruction with Autologous Fat Transfer.
Wederfoort JLM, Schop S, van der Broeck LCA, Hommes JE, et al · · 2024 · cited 4× · PMID 37114918 · DOI 10.1097/prs.0000000000010619
Postmastectomy Breast Reconstruction in Patients with Non-Metastatic Breast Cancer: A Systematic Review.
Zhong T, Fletcher GG, Brackstone M, Frank SG, et al · · 2025 · cited 2× · PMID 40277787 · DOI 10.3390/curroncol32040231
Postmastectomy Breast Reconstruction in Patients with Non-Metastatic Breast Cancer: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline.
Zhong T, Fletcher GG, Brackstone M, Frank SG, et al · · 2025 · cited 1× · PMID 40558300 · DOI 10.3390/curroncol32060357
Bilateral breast infection following total breast reconstruction with autologous fat transfer (AFT): A case report.
Saelmans AG, Rijkx M, Hommes J, van der Hulst R, et al · · 2023 · cited 1× · PMID 36812827 · DOI 10.1016/j.ijscr.2023.107917

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Maastricht University Medical Center trials

Trials by the same sponsor.

NCT04603261 — Time to Excretion of Contrast, a Maastricht Prospective Observational Study · withdrawn
NCT04598516 — Maastricht Investigation of Renal Function in Absence of- and Post- Contrast in Patients With eGFR LEss Than 30 · withdrawn
NCT04597892 — Efficacy of Point-Of-Care Creatinine Assays in Patients With eGFR <30 Receiving Intravascular Contrast · withdrawn
NCT07287358 — Optimal Cerebral Perfusion Pressure Guided Therapy: Assessment of Target Effectiveness - II · NA · not yet recruiting
NCT07501780 — Real-world Evaluation of the Implementation of LC-OCT in Daily Clinical Practice · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02339779 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Maastricht University Medical Center
Last refreshed: 3 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02339779.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing